Plant Advanced Technologies（ALPAT）株式概要Plant Advanced Technologies SAは植物バイオテクノロジー企業で、フランスで化粧品、医薬品、農薬市場向けの活性剤を生産・販売している。 詳細ALPAT ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績3/6財務の健全性1/6配当金0/6報酬株価収益率（ 8.4 x） French市場（ 15.9 x）を下回っています。過去1年間で収益は1081.2%増加しました リスク分析最新の財務報告は1年以上前のものである 意味のある時価総額がありません ( €8M )財務結果に影響を与える大きな一時的項目 意味のある収益がありません ( €2M )+1 さらなるリスクすべてのリスクチェックを見るALPAT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€7.0042.0% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-1m3m2016201920222025202620282031Revenue €2.2mEarnings €935.1kAdvancedSet Fair ValueView all narrativesPlant Advanced Technologies SA 競合他社Oncodesign Precision Medicine Société anonymeSymbol: ENXTPA:ALOPMMarket cap: €7.7mgenOway Société anonymeSymbol: ENXTPA:ALGENMarket cap: €22.6mEurobio Scientific Société anonymeSymbol: ENXTPA:ALERSMarket cap: €223.5mCardiogeniSymbol: OFEX:CGNIMarket cap: UK£6.7m価格と性能株価の高値、安値、推移の概要Plant Advanced Technologies過去の株価現在の株価€7.0052週高値€11.4552週安値€5.84ベータ0.841ヶ月の変化0.72%3ヶ月変化-16.07%1年変化-36.07%3年間の変化-47.76%5年間の変化-69.03%IPOからの変化-46.97%最新ニュースNew Risk • May 02New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Market cap is less than US$10m (€7.74m market cap, or US$9.07m). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m).New Risk • Apr 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€8.62m market cap, or US$9.92m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (7.3% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.5m).Valuation Update With 7 Day Price Move • Apr 01Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €7.68, the stock trades at a trailing P/E ratio of 9.2x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total loss to shareholders of 39% over the past three years.Valuation Update With 7 Day Price Move • Mar 10Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €7.04, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 42% over the past three years.New Risk • Mar 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.06m (US$9.36m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€8.06m market cap, or US$9.36m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m).New Risk • Jan 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.57m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€8.57m market cap, or US$9.97m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m).最新情報をもっと見るRecent updatesNew Risk • May 02New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Market cap is less than US$10m (€7.74m market cap, or US$9.07m). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m).New Risk • Apr 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€8.62m market cap, or US$9.92m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (7.3% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.5m).Valuation Update With 7 Day Price Move • Apr 01Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €7.68, the stock trades at a trailing P/E ratio of 9.2x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total loss to shareholders of 39% over the past three years.Valuation Update With 7 Day Price Move • Mar 10Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €7.04, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 42% over the past three years.New Risk • Mar 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.06m (US$9.36m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€8.06m market cap, or US$9.36m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m).New Risk • Jan 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.57m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€8.57m market cap, or US$9.97m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m).New Risk • Nov 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m). Market cap is less than US$100m (€9.52m market cap, or US$11.1m).New Risk • Apr 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (€11.5m market cap, or US$12.6m).お知らせ • May 27Plant Advanced Technologies SA, Annual General Meeting, Jun 28, 2024Plant Advanced Technologies SA, Annual General Meeting, Jun 28, 2024. Location: amphitheatre cuenot de l ensaia de l universite, de lorraine, 2 avenue de la foret de haye, vandoeuvre les nancy FranceNew Risk • Apr 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Revenue is less than US$5m (€2.3m revenue, or US$2.5m). Market cap is less than US$100m (€11.5m market cap, or US$12.4m).お知らせ • Jan 10Plant Advanced Technologies Announces the Official Launch of Its Latest Active Ingredient, Hydraqueen Exudactive®?1,3, and the Upcoming Cosmetic Range as Part of Its New Business StrategyPlant Advanced Technologies announced the official launch of its latest active ingredient, HydraQueen Exudactive®?1,3, and the upcoming cosmetic range as part of its new business strategy. The latest ingredient in the PAT Exudactive ®? collection, is extracted from meadowsweet root, a natural treasure full of molecules with proven biological activities for the skin. Its richness in secondary metabolites, multiplied by 82 due to the stimulation operation, makes it a real concentrate of benefits for the epidermis. This ingredient was carefully developed over several years by PAT teams and is the result of expertise in research engineering and optimization of plants grown and harvested in its aeroponic greenhouses. Innovative active ingredients that repair the skin barrier: a growing niche in Cosmetics This natural active ingredient is rich in molecules from the roots of the plant. Efficacy tests have demonstrated the benefits of HydraQueen Exudactive®®? for the skin: Restoration of the fragile balance of the skin's barrier function (+52% on D14); Helps defend the skin against pollution (TEER +17% on stressed mature skin), dehydration and environmental stress; Maintenance of internal hydration (+60% on day 14) and protection against external irritants; Helps repair and strengthen sensitive skin. Responsible innovation at the heart of PAT products: Responsible innovation is at the heart of Plant Advanced Technologies' approach. The Group has two unique research centers, one in Lorraine, the other on Reunion Island. These centers explore the products of tomorrow, while ensuring that nature and natural resources are preserved. With HydraQueen Exudactive®, PAT strives to preserve nature while offering the best of its activities thanks to production methods that respect the environment and natural resources: by the economy of cultivated areas - with 4 annual harvests and a life expectancy of at least 3 years in aeroponics By limiting water by recycling 100% of the culture water (closed cycle) By reasoned cultivation in biological control and biocontrol in a natural greenhouse - Zero pesticide By multiplying by 96 times the quantity of molecules collected VS in open fields. A sustainable sourcing and production chain to meet customers’ expectations HydraQueen Exudactive® ingredient is manufactured in France, with a fully controlled production chain traced from seed to active ingredient on the PAT site, thus guaranteeing: - quality: all of the company's activities are ISO9001-2015 certified, horticultural activities and aeroponic cultivation in Lorraine are labeled High Environmental Value (HVE) level 3. origin and transparency: PAT ingredients are RSPO MB certified, and all plants are sourced according to the Nagoya protocol in force, which aims to protect global biodiversity. “naturalness”: The ingredients are COSMOS and ISO16128 compatible – 100% natural origin.New Risk • Nov 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (€7.72m market cap, or US$8.36m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (€2.3m revenue, or US$2.5m).Major Estimate Revision • Oct 27Consensus revenue estimates fall by 20%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €3.00m to €2.40m. Forecast loss of -€0.62, down from profit of €0.14 per share profit previously. Biotechs industry in France expected to see average net income growth of 21% next year. Consensus price target down from €24.60 to €15.70. Share price fell 30% to €6.75 over the past week.Breakeven Date Change • Oct 26Forecast breakeven date pushed back to 2025The analyst covering Plant Advanced Technologies previously expected the company to break even in 2023. New forecast suggests the company will make a profit of €1.20m in 2025. Average annual earnings growth of 100% is required to achieve expected profit on schedule.New Risk • Oct 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Market cap is less than US$10m (€7.99m market cap, or US$8.46m). Minor Risk Revenue is less than US$5m (€2.3m revenue, or US$2.5m).Board Change • Nov 16No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). Representative Director Michael Donabedian was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Nov 06First half 2022 earnings released: €0.97 loss per share (vs €1.00 loss in 1H 2021)First half 2022 results: €0.97 loss per share (improved from €1.00 loss in 1H 2021). Revenue: €2.00m (up 7.2% from 1H 2021). Net loss: €1.05m (loss narrowed 3.0% from 1H 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Breakeven Date Change • May 16Forecast to breakeven in 2023The analyst covering Plant Advanced Technologies expects the company to break even for the first time. New forecast suggests losses will reduce by 82% to 2022. The company is expected to make a profit of €800.0k in 2023. Average annual earnings growth of 136% is required to achieve expected profit on schedule.Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). Representative Director Michael Donabedian was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Price Target Changed • Nov 24Price target decreased to €27.70Down from €31.40, the current price target is provided by 1 analyst. New target price is 41% above last closing price of €19.65. Stock is up 6.8% over the past year. The company is forecast to post a net loss per share of €0.95 next year compared to a net loss per share of €0.61 last year.お知らせ • Mar 16Plant Advanced Technologies SA to Report Fiscal Year 2020 Results on May 01, 2021Plant Advanced Technologies SA announced that they will report fiscal year 2020 results on May 01, 2021Is New 90 Day High Low • Jan 06New 90-day high: €21.40The company is up 12% from its price of €19.10 on 08 October 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 27% over the same period.Is New 90 Day High Low • Dec 22New 90-day high: €20.80The company is up 4.0% from its price of €20.00 on 22 September 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 32% over the same period.分析記事 • Dec 02Here's Why Plant Advanced Technologies (EPA:ALPAT) Can Afford Some DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Is New 90 Day High Low • Nov 16New 90-day low: €16.90The company is down 15% from its price of €19.80 on 18 August 2020. The French market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period.Is New 90 Day High Low • Oct 13New 90-day low: €18.30The company is down 7.0% from its price of €19.60 on 15 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period.お知らせ • Sep 22Plant Advanced Technologies SA to Report First Half, 2020 Results on Oct 30, 2020Plant Advanced Technologies SA announced that they will report first half, 2020 results on Oct 30, 2020株主還元ALPATFR BiotechsFR 市場7D3.7%3.4%2.0%1Y-36.1%344.2%1.3%株主還元を見る業界別リターン: ALPAT過去 1 年間で344.2 % の収益を上げたFrench Biotechs業界を下回りました。リターン対市場: ALPATは、過去 1 年間で1.3 % のリターンを上げたFrench市場を下回りました。価格変動Is ALPAT's price volatile compared to industry and market?ALPAT volatilityALPAT Average Weekly Movement8.5%Biotechs Industry Average Movement9.3%Market Average Movement5.4%10% most volatile stocks in FR Market10.7%10% least volatile stocks in FR Market2.9%安定した株価: ALPATの株価は、 French市場と比較して過去 3 か月間で変動しています。時間の経過による変動: ALPATの weekly volatility ( 8% ) は過去 1 年間安定していますが、依然としてFrenchの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200516Jean-Paul Fevrewww.plantadvanced.com植物バイオテクノロジー企業であるPlant Advanced Technologies SA社は、フランスで化粧品、医薬品、農薬市場向けの活性剤を生産・販売している。同社の技術には、植物を保存しながら植物刺激と生きた根の滲出によって活性エキスを生産するPAT Plant Milkingや、酵素などの目的のタンパク質標的に結合するリガンドを見つけるPAT Target Bindingなどがある。同社は2005年に設立され、フランスのヴァンドゥーブル・レ・ナンシーに本社を置いている。もっと見るPlant Advanced Technologies SA 基礎のまとめPlant Advanced Technologies の収益と売上を時価総額と比較するとどうか。ALPAT 基礎統計学時価総額€7.85m収益（TTM）€935.13k売上高(TTM)€2.22m8.4xPER（株価収益率3.5xP/SレシオALPAT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ALPAT 損益計算書（TTM）収益€2.22m売上原価€527.46k売上総利益€1.69mその他の費用€752.56k収益€935.13k直近の収益報告Dec 31, 2024次回決算日該当なし一株当たり利益（EPS）0.83グロス・マージン76.19%純利益率42.22%有利子負債／自己資本比率37.4%ALPAT の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 12:00終値2026/05/22 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Plant Advanced Technologies SA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Charles-Louis PlanadeTPICAP MidcapFlorent Thy-TineTPICAP MidcapClaire DerayTPICAP Midcap
New Risk • May 02New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Market cap is less than US$10m (€7.74m market cap, or US$9.07m). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m).
New Risk • Apr 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€8.62m market cap, or US$9.92m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (7.3% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.5m).
Valuation Update With 7 Day Price Move • Apr 01Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €7.68, the stock trades at a trailing P/E ratio of 9.2x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total loss to shareholders of 39% over the past three years.
Valuation Update With 7 Day Price Move • Mar 10Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €7.04, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 42% over the past three years.
New Risk • Mar 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.06m (US$9.36m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€8.06m market cap, or US$9.36m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m).
New Risk • Jan 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.57m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€8.57m market cap, or US$9.97m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m).
New Risk • May 02New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Market cap is less than US$10m (€7.74m market cap, or US$9.07m). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m).
New Risk • Apr 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€8.62m market cap, or US$9.92m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (7.3% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.5m).
Valuation Update With 7 Day Price Move • Apr 01Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €7.68, the stock trades at a trailing P/E ratio of 9.2x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total loss to shareholders of 39% over the past three years.
Valuation Update With 7 Day Price Move • Mar 10Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €7.04, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 42% over the past three years.
New Risk • Mar 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.06m (US$9.36m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€8.06m market cap, or US$9.36m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m).
New Risk • Jan 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.57m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€8.57m market cap, or US$9.97m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m).
New Risk • Nov 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (€2.2m revenue, or US$2.6m). Market cap is less than US$100m (€9.52m market cap, or US$11.1m).
New Risk • Apr 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (€11.5m market cap, or US$12.6m).
お知らせ • May 27Plant Advanced Technologies SA, Annual General Meeting, Jun 28, 2024Plant Advanced Technologies SA, Annual General Meeting, Jun 28, 2024. Location: amphitheatre cuenot de l ensaia de l universite, de lorraine, 2 avenue de la foret de haye, vandoeuvre les nancy France
New Risk • Apr 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Revenue is less than US$5m (€2.3m revenue, or US$2.5m). Market cap is less than US$100m (€11.5m market cap, or US$12.4m).
お知らせ • Jan 10Plant Advanced Technologies Announces the Official Launch of Its Latest Active Ingredient, Hydraqueen Exudactive®?1,3, and the Upcoming Cosmetic Range as Part of Its New Business StrategyPlant Advanced Technologies announced the official launch of its latest active ingredient, HydraQueen Exudactive®?1,3, and the upcoming cosmetic range as part of its new business strategy. The latest ingredient in the PAT Exudactive ®? collection, is extracted from meadowsweet root, a natural treasure full of molecules with proven biological activities for the skin. Its richness in secondary metabolites, multiplied by 82 due to the stimulation operation, makes it a real concentrate of benefits for the epidermis. This ingredient was carefully developed over several years by PAT teams and is the result of expertise in research engineering and optimization of plants grown and harvested in its aeroponic greenhouses. Innovative active ingredients that repair the skin barrier: a growing niche in Cosmetics This natural active ingredient is rich in molecules from the roots of the plant. Efficacy tests have demonstrated the benefits of HydraQueen Exudactive®®? for the skin: Restoration of the fragile balance of the skin's barrier function (+52% on D14); Helps defend the skin against pollution (TEER +17% on stressed mature skin), dehydration and environmental stress; Maintenance of internal hydration (+60% on day 14) and protection against external irritants; Helps repair and strengthen sensitive skin. Responsible innovation at the heart of PAT products: Responsible innovation is at the heart of Plant Advanced Technologies' approach. The Group has two unique research centers, one in Lorraine, the other on Reunion Island. These centers explore the products of tomorrow, while ensuring that nature and natural resources are preserved. With HydraQueen Exudactive®, PAT strives to preserve nature while offering the best of its activities thanks to production methods that respect the environment and natural resources: by the economy of cultivated areas - with 4 annual harvests and a life expectancy of at least 3 years in aeroponics By limiting water by recycling 100% of the culture water (closed cycle) By reasoned cultivation in biological control and biocontrol in a natural greenhouse - Zero pesticide By multiplying by 96 times the quantity of molecules collected VS in open fields. A sustainable sourcing and production chain to meet customers’ expectations HydraQueen Exudactive® ingredient is manufactured in France, with a fully controlled production chain traced from seed to active ingredient on the PAT site, thus guaranteeing: - quality: all of the company's activities are ISO9001-2015 certified, horticultural activities and aeroponic cultivation in Lorraine are labeled High Environmental Value (HVE) level 3. origin and transparency: PAT ingredients are RSPO MB certified, and all plants are sourced according to the Nagoya protocol in force, which aims to protect global biodiversity. “naturalness”: The ingredients are COSMOS and ISO16128 compatible – 100% natural origin.
New Risk • Nov 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (€7.72m market cap, or US$8.36m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (€2.3m revenue, or US$2.5m).
Major Estimate Revision • Oct 27Consensus revenue estimates fall by 20%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €3.00m to €2.40m. Forecast loss of -€0.62, down from profit of €0.14 per share profit previously. Biotechs industry in France expected to see average net income growth of 21% next year. Consensus price target down from €24.60 to €15.70. Share price fell 30% to €6.75 over the past week.
Breakeven Date Change • Oct 26Forecast breakeven date pushed back to 2025The analyst covering Plant Advanced Technologies previously expected the company to break even in 2023. New forecast suggests the company will make a profit of €1.20m in 2025. Average annual earnings growth of 100% is required to achieve expected profit on schedule.
New Risk • Oct 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Market cap is less than US$10m (€7.99m market cap, or US$8.46m). Minor Risk Revenue is less than US$5m (€2.3m revenue, or US$2.5m).
Board Change • Nov 16No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). Representative Director Michael Donabedian was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 06First half 2022 earnings released: €0.97 loss per share (vs €1.00 loss in 1H 2021)First half 2022 results: €0.97 loss per share (improved from €1.00 loss in 1H 2021). Revenue: €2.00m (up 7.2% from 1H 2021). Net loss: €1.05m (loss narrowed 3.0% from 1H 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in France. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Breakeven Date Change • May 16Forecast to breakeven in 2023The analyst covering Plant Advanced Technologies expects the company to break even for the first time. New forecast suggests losses will reduce by 82% to 2022. The company is expected to make a profit of €800.0k in 2023. Average annual earnings growth of 136% is required to achieve expected profit on schedule.
Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). Representative Director Michael Donabedian was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Price Target Changed • Nov 24Price target decreased to €27.70Down from €31.40, the current price target is provided by 1 analyst. New target price is 41% above last closing price of €19.65. Stock is up 6.8% over the past year. The company is forecast to post a net loss per share of €0.95 next year compared to a net loss per share of €0.61 last year.
お知らせ • Mar 16Plant Advanced Technologies SA to Report Fiscal Year 2020 Results on May 01, 2021Plant Advanced Technologies SA announced that they will report fiscal year 2020 results on May 01, 2021
Is New 90 Day High Low • Jan 06New 90-day high: €21.40The company is up 12% from its price of €19.10 on 08 October 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 27% over the same period.
Is New 90 Day High Low • Dec 22New 90-day high: €20.80The company is up 4.0% from its price of €20.00 on 22 September 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 32% over the same period.
分析記事 • Dec 02Here's Why Plant Advanced Technologies (EPA:ALPAT) Can Afford Some DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Is New 90 Day High Low • Nov 16New 90-day low: €16.90The company is down 15% from its price of €19.80 on 18 August 2020. The French market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period.
Is New 90 Day High Low • Oct 13New 90-day low: €18.30The company is down 7.0% from its price of €19.60 on 15 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period.
お知らせ • Sep 22Plant Advanced Technologies SA to Report First Half, 2020 Results on Oct 30, 2020Plant Advanced Technologies SA announced that they will report first half, 2020 results on Oct 30, 2020
